Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, James L Wade, William J Irvin, Sreekanth C Reddy, Jeffrey Crawford, Jeffrey D Bradley, Thomas E Stinchcombe, Suresh S Ramalingam, Jieling Miao, Katherine Minichiello, Roy S Herbst, Vassiliki A Papadimitrakopoulou, Karen Kelly, David R Gandara
Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002973; DOI: 10.1136/jitc-2021-002973